AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05244057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Interferon alfa 2a
Description: 90ug, s.c., qw for 48 weeks
Study NCT05244057 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pegylated Interferon alfa 2a
Description: 90ug, s.c., qw for 48 weeks
Study NCT06328647 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: POC Quantra QPlus System
Description: The POC Quantra QPlus System will be located in the operating room. Samples will be processed by trained (certified for POC testing) personnel and interpreted by the primary anesthesia team. The anesthesia team will perform a baseline hemostatic assessment , approximately 15 min prior to separation from CPB, and again 10-20 min following protamine administration using the Quantra POC hemostasis monitor. If persistent bleeding occurs despite clinical management, coagulation will be rechecked by a repeated Quantra assessment and treated as necessary. A Quantra device will be placed in the ICU for assessment for the first 6 hours following surgery.
Study NCT06328647 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine care
Description: Blood and blood component transfusions will be determined by provider preference based on clinical findings. The anesthesia caregiver will perform laboratory testing for coagulation management at his/her discretion. Usual laboratory testing may include assessment of TEG with heparinase, platelet count, fibrinogen concentration at approximately 30-40 min prior to separation from cardiopulmonary bypass. Another set of laboratory tests may be sent post-CPB including TEG, platelet count, fibrinogen concentration, PT/aPTT, INR. Anesthesia caregiver will treat clinical bleeding and coagulopathy at his/her discretion.
Study NCT06327321 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deucravacitinib
Description: Throughout the study, there will be a total of six visits conducted: selection, inclusion, Week 12, Week 24, Week 36, and Week 48. In patients who volunteer, a skin biopsy will be performed on both the lesional and peri-lesional areas at baseline, Week 12 and Week 36. Serum and plasma samples will be collected at the screening visit, Week 12, Week 24, Week 36, and Week 48.
Study NCT06327321 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Volunteer without treatment
Description: Throughout the study, there will be a total of six visits conducted: selection, inclusion, Week 12, Week 24, Week 36, and Week 48. In patients who volunteer, a skin biopsy will be performed on both the lesional and peri-lesional areas at baseline, Week 12 and Week 36. Serum and plasma samples will be collected at the screening visit, Week 12, Week 24, Week 36, and Week 48.
Study NCT05208931 — intervention group
Intervention type: PROCEDURE
Intervention: Anti-vascular endothelial growth factor therapy
Description: 0.05 ml anti-VEGF, intravitreal, monthly
Study NCT06635772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-10390
Description: HS-10390 will be administered daily
Study NCT06635772 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irbesartan
Description: Irbesartan will be administered daily as a 150-mg oral tablet. For patients who tolerate the initial dose of 150 mg after 2 weeks will increase their dose to 300 mg
Study NCT06636513 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: SMT04 (M3XTRA)
Description: This is a pilot prospective single-arm, open-label clinical trial to assess the effect of the probiotic SMT04 (M3XTRA) on the gut microbiome and relief of IBS symptoms.
Study NCT06635174 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dextrose
Description: we are using 2ml of 50% dextrose
Study NCT06635174 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: normal water
Description: patient will receive 2ml of normal water
Study NCT06635798 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GR2001
Description: The packaging for GR2001 injection uses a borosilicate glass vial, a brominated halobutyl rubber stopper for injectable solutions and an aluminum-plastic combination cap for antibiotic vials as its primary packaging materials. The specification is 5mg/1ml per vial.
Study NCT06635798 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: HTIG
Description: The HTIG is a Chinese licensed Human Tetanus Immunoglobulin produced by Tonglu-Bio, which are derived from human plasma, and then purified and filled in the injectable vial form.
Study NCT06326606 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Psilocybin
Description: Capsule containing active ingredient, psilocybin
Study NCT06439615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib 4 MG
Description: Baricitinib will be administered orally (or crushed for nasogastric tube delivery) at a daily dosage of 4mg for three consecutive days following SAH.
Study NCT06439615 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard treatment
Description: Participants will receive standard treatment and care according to the current management guidelines for subarachnoid hemorrhage.
Study NCT06439615 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Standard treatment
Description: Participants will receive standard treatment and care according to the current management guidelines for subarachnoid hemorrhage.
Study NCT06265285 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home Health Encounter
Description: Receive in-home visits by a home health nurse
Study NCT06265285 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given SC
Study NCT06265285 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Patient Monitoring
Description: Undergo remote patient monitoring
Study NCT06265285 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT06326606 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsule with no active ingredients
Study NCT04848025 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Custom-designed tracheobronchial prostheses
Description: Computer-assisted segmentation of airways and stent from CT data (AnatomikModeling) Fabrication of a mold and then a silicon stent by mold injection and sterilization (NOVATECH) Insertion of the stent under rigid bronchoscopy and general anesthesia
Study NCT05997693 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor 90 MG
Description: Ticagrelor 90 mg twice daily taken orally for one month
Study NCT05997693 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low-dose aspirin
Description: 75-150 mg once daily taken orally
Study NCT05997693 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low-dose aspirin
Description: 75-150 mg once daily taken orally
Study NCT05688813 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Regional anesthesia intervention
Description: Ultrasound-guided caudal and sacral erector spinae blocks were administered
Study NCT04989998 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hip7 Software on Kick/ CORI platforms
Description: Total hip arthroplasty surgery using Hip7 software on Kick or CORI platforms using R3 Polarstem implants.
Study NCT04989998 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional surgical procedures
Description: THA surgery using standard, manual instrumentation and digital templating techniques using R3 polarstem implants.
Study NCT05515302 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Audio Clip
Description: Selected Audio clips will be introduced to the study subjects during the Burns Dressing Changes. The Audio Clips will be selected as per subjects preference.
Study NCT05877729 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: The SOC arm will include the current care delivery model: regularly scheduled visits with a healthcare provider and lab testing every 3-6 months or more/less frequently depending on the individual's HIV health outcomes (e.g., VL suppression). At each assessment, the investigators will review 149 SOC participant responses to examine acute need for referral for medical, psychological, or substance use services. In between assessments, the investigators will also do monthly check-ins to improve retention and check contact information.
Study NCT05877729 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video-counseling+app
Description: The intervention tailors the telehealth counseling according to the individual's needs. Tailoring occurs based on the participant's baseline MH, SU, and HIV knowledge/outcomes and assessment responses inform the sessions on these topics. Participants choose from a list identified in the menu sessions: HIV care, MH, SU, lifestyle, health, social support, family of origin, romantic and sexual relationships, self-identity and disclosure, subsistence needs, education and vocation, and a wildcard session.~WYZ contains 3 main features: My Health, My Team, and My Community. Tailoring is achieved based on the individual's needs at a given time (e.g., My Community may be used more if social isolation is a barrier).
Study NCT05211752 — intervention group
Intervention type: OTHER
Intervention: eVOG (Mobile VideoOculoGraphy)
Description: * Eyes movements assessed with e-VOG (mobile application, that uses the face detection features of the front camera to detect and record eye movements).~* Study duration is about 20 minutes, the day the subject performs his standard video-oculography examination in routine care (using Eye-Tracker®T2)
Study NCT04271683 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pressure controlled ventilation with PEEP
Description: The intervention consists of starting ventilation after apnoea during induction of general anesthesia with pressure controlled ventilation with PEEP instead of manually without PEEP.
Study NCT04271683 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Manual ventilation without PEEP
Description: The intervention consists of starting ventilation after apnoea during induction of general anesthesia manually instead of with pressure controlled ventilation with PEEP.
Study NCT06397404 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Venous excess ultrasound score (VExUS) protocol
Description: All patients upon admission undergo ultrasound assessment of diameter and collapsibility of the inferior vena cava, hepatic vein Doppler, portal vein Doppler, intra-renal venous Doppler.
Study NCT04947020 — intervention group
Intervention type: DRUG
Intervention: Metformin
Description: Metformin use before operation due to previously diagnosed diabetes.
Study NCT06160882 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Powered Prosthesis Training and EMG data collection
Description: Participants are fit for a custom instrumented socket for collection of surface EMG signals and use with the powered lower limb prosthesis.~EMG control sites will be located using clinical best practices. Once socket fit is completed, the prosthetist will attach and align the powered prosthesis. The participant will be instructed to walk with the powered prosthesis for level ground walking, incline walking, stair climbing and non-weight bearing independence control activities. A non-weight bearing independent control system will be configured. These data are used to train a pattern recognition control system which can control the leg knee and ankle joints respectively, either in a virtual environment or with the physical prosthesis The participants will complete functional, biomechanical, metabolic, and patient reported outcome measures.
Study NCT06160882 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Perform Osseointegration (OI) surgery and Targeted Muscle Reinnervation (TMR)
Description: Participants will undergo OI Surgery 1 +TMR and recovery. Following recovery, participants will receive OI surgery 2 where the abutment is connected to the fixture with in the femur. Participants will receive standard post-surgical care and participate in the OPRA rehab program through the Shirley Ryan AbilityLab. The participant uses their clinically prescribed prosthetic knee unit for training in the OPRA rehab program.~Post-Surgery Fitting and Powered Leg Prosthesis Training: EMG signals are measured using a custom fit electrode band on the residual limb that is tethered to the prosthesis. Participants are fit with the powered prosthesis using their OI interface and trained on its use. The participant will complete non-weight-bearing neural control tasks as done prior to surgery. The participants will complete functional, biomechanical, metabolic, and patient-reported outcome measures using the OI interface and the powered leg prosthesis.
Study NCT05979051 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1703
Description: SHR-1703 will be administered by Subcutaneous injection in Phase 2 and Phase 3.
Study NCT05979051 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SHR-1703 Placebo
Description: SHR-1703 Placebo will be administered by Subcutaneous injection in Phase 3.
Study NCT05202314 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immunotherapy (Camrelizumab)
Description: After clinical success of colonic stenting, regardless of the MSI state, patients will receive Immunotherapy (Camrelizumab 200mg) for 2 cycles compined with neoadjuvant chemotherapy with mFOLFOX6 regimen for 3 cycles or CapeOx regimen for 2 cycles. Patients will undergo surgery 2-3 weeks after the last cycle chemotherapy
Study NCT06033027 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Carbonhand
Description: During this phase, participants use the Carbonhand soft-robotic glove system in daily life for 6 weeks to support the performance of daily activities with their affected hand in the home environment. The participants are free to choose for which activities, when and for how long they use the Carbonhand. However, it is recommended to use the Carbonhand at least 180 minutes a week during the most common ADL, such as household activities, dressing/undressing, eating/drinking/cooking, and/or leisure activities.
Study NCT05721716 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Booster Course
Description: The mindfulness booster course will consist of eight 30-minute sessions, which participants will be asked to commit to. These will be online and occur weekly for 8-weeks. Within these sessions, there will be a 15-minute mindfulness practice followed by a 15-minute discussion. This discussion time will involve reflecting on the mindfulness practice and speaking about between-session practice. Participants will be encouraged to practice mindfulness for home work between the sessions.
Study NCT05721716 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual care
Description: Participants will be encouraged to continue with whatever activities they usually undertake to manage their stress and support their wellbeing.
Study NCT05721716 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Usual care
Description: Participants will be encouraged to continue with whatever activities they usually undertake to manage their stress and support their wellbeing.
Study NCT06532487 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Critical Time Medical-Legal Partnership Intervention
Description: Utilizing a hybrid type II effectiveness-implementation trial with a cluster randomized design in six predominantly Latino-serving federally qualified health centers (FQHCs) in three major urban settings, we are examining whether integrating legal services into existing health clinics that serve Latinx and recent migrant communities can improve engagement in care and improve the health of Latinx/Hispanic and recent migrants.
Study NCT04986657 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ChromoSeq
Description: Novel, streamlined whole genome sequencing approach
Study NCT04282044 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CRX100 suspension for infusion
Description: A fixed dose of CIK cells combined with the specified dose of CDSR.
Study NCT04282044 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 25mg/m IV (five doses given from Day -7 until Day -3)
Study NCT04282044 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 60mg/kg intravenous (IV) (two doses given on Day -7 and -6)
Study NCT05732168 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: A test battery for evaluation of muscle strength, balance and functional performance
Description: Subjects with chronic ankle instability (CAI) were evaluated with five tests of strength, balance and functional performance.
Study NCT06371885 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: shock wave therapy
Description: shock wave therapy will be applied one session per week, each ESWT session will involve 2,000 pulses of the focus probe at 4-bar pressure and 5 Hz frequency for twelve weeks
Study NCT06371885 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: traditional physical therapy
Description: the traditional physical therapy will be in form of (10 minutes hot pack around wrist and forearm and 10 minutes of gentle stretching exercises for wrist joint, three sessions per week for twelve weeks
Study NCT06542627 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Freestyle Libre
Description: Glycemic control was monitored using CGM data for two weeks, followed by individualized dietary education.
Study NCT06543160 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Immediate SSC and early breastfeeding during CS
Description: Upon birth, the neonate is promptly placed prone on the mother's chest, with their head turned to one side for optimal skin contact. The drying process begins within 5 seconds and is completed within 20 to 30 seconds while the neonate remains on the mother's chest. Delayed cord clamping is practiced, with the cord clamped approximately 1-3 minutes after birth. Breastfeeding cues such as tongue movements or head turning are monitored, and the obstetric nurse assists the mother in initiating breastfeeding as soon as possible. SSC continues throughout the cesarean procedure, and upon completion, the newborn is temporarily separated from the mother for safety during transfer to the surgical cart. SSC is resumed immediately post-transfer and continues for a cumulative duration of at least 90 minutes. The neonate's skin color, breathing, and feeding responses are continuously observed.
Study NCT06543160 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Delayed SSC and breastfeeding after CS
Description: The neonate is dried within 20-30 seconds after birth, the cord is clamped after 1-3 minutes, and then the neonate is sent to the ward to wait for the mother to complete the surgery. Immediate SSC is initiated within one hour after birth and maintained with the mother for at least 90 minutes post-surgery, during which the neonate's skin color and breathing are continuously monitored. The obstetric nurse supports the mother in initiating breastfeeding at the earliest opportunity.
Study NCT06543160 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Routine newborn care
Description: Newborn eye care, vitamin K1 administration, immunizations, weighing, and standard examinations are conducted before the neonate is transferred to the ward.
Study NCT06543160 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Routine newborn care
Description: Newborn eye care, vitamin K1 administration, immunizations, weighing, and standard examinations are conducted before the neonate is transferred to the ward.
Study NCT05723341 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacain
Description: %0,25
Study NCT05723341 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: In this group, patients will be postoperatively administered patient-controlled analgesia with morphine only.
Study NCT04989621 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orelabrutinib and Rituximab
Description: Orelabrutinib 150mg po qd d1-28; Rituximab 375mg/m2 iv.drip d1.
Study NCT04989621 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orelabrutinib
Description: Orelabrutinib 150mg po qd
Study NCT05012735 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Study Cleanser (Neutrogena Ultra Gentle Daily Cleanser with Pro Vitamin B5)
Description: Participants will wash their face with the study cleanser (Neutrogena Ultra Gentle Daily Cleanser with Pro Vitamin B5) for up to 14 days.
Study NCT05012735 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Study Cleanser (Neutrogena Ultra Gentle Daily Cleanser with Pro Vitamin B5)
Description: Participants will wash their face with the study cleanser (Neutrogena Ultra Gentle Daily Cleanser with Pro Vitamin B5) for up to 14 days.
Study NCT05012735 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prototype Ultrathin Hydrocolloid Bandage
Description: Participants will cover their closed and popped pimples in the evening with one or two bandages from Days 0 through 6.
Study NCT06243081 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: intervention group (Flipped Teaching Method Group)
Description: Students will be given skill training with the Flipped Teaching method, which consists of outside and in-class applications.~Out-of-Class Practice: A Learning Management System-Web-Based Distance Education System will be created for the Flipped Teaching method. Theoretical course topics and skill training videos will be uploaded to the system 7 days before the course day. Students will be able to watch the video tutorials in the number and frequency they want until the day of the lesson. At the end of the lesson, the mini-exam will be uploaded to the system.~In-class practice: The researcher will come to the lesson prepared for classroom activities such as question and answer. Theoretical lectures and skill demonstrations will not be made by the researcher. The researcher will only guide the students. Then, the students will be provided to perform the skill under the guidance of the researcher in the clinical skills laboratory.